Showing 1641-1650 of 3020 results for "".
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our n
- Caliber Imaging & Diagnostics Receives $1.4 Million Order for VivaScope® Systems From European Distributor MAVIG GmbHhttps://practicaldermatology.com/news/20140114-caliber_imaging__diagnostics_receives_14_million_order_for_vivascope_systems_from_european_distributor_mavig_gmbh/2459373/Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., announces receipt of $1.4 million in orders for VivaScope® systems from its European distributor MAVIG GmbH. These units are scheduled to be shipped in the first half of 2014. MAVIG has been Caliber's exclusive distributor in Europe f
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- Cutera Appoints Scott Ashworth as Executive Vice President of Global Saleshttps://practicaldermatology.com/news/20131230-cutera_appoints_scott_ashworth_as_executive_vice_president_of_global_sales/2459385/Scott Ashworth recently joined Cutera as Executive Vice President of Global Sales. He brings twenty-five years of experience in building and leading global sales and marketing teams focused on commercialization of products, establishing distributio
- FDA Clears Scar Management Gel from Oculus and Quinnovahttps://practicaldermatology.com/news/20131204-fda_clears_scar_management_gel_from_oculus_and_quinnova/2459398/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for Microcyn Scar Management HydroGel, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures, and trauma wounds. Oculus U.S. dermatology partner, Quinnova
- AAD Issues New Guidelines for Diagnosis and Assessment of Atopic Dermatitishttps://practicaldermatology.com/news/20131204-aad_issues_new_guidelines_for_diagnosis_and_assessment_of_atopic_dermatitis/2459399/The American Academy of Dermatology (AAD) recently announced the release of its new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy, re
- Onset Dermatologics Acquires Worldwide Rights to Clindagel from Galderma Laboratorieshttps://practicaldermatology.com/news/20131031-onset_dermatologics_acquires_worldwide_rights_to_clindagel_from_galderma_laboratories/2459425/Onset Dermatologics, LLC recently announced the acquisition of Clindagel (clindamycin phosphate gel 1%), a prescription topical antibiotic for the treatment of acne, from Galderma Laboratories. Clindagel is the only FDA-approved topical form
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or
- Differin Gel Found Effective in Adult Women with Acnehttps://practicaldermatology.com/news/20130807-differin_gel_found_effective_in_adult_women_with_acne/2459483/At the recent AAD Summer Meeting in New York, Galderma Laboratories presented results showing that Differin® (adapalene) Gel, 0.3% is efficacious in reducing acne lesions in adult women, and has been proven superior in reducing inflammatory lesions in women compared with vehicle gel. Investigators u
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t